<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03313661</url>
  </required_header>
  <id_info>
    <org_study_id>Diabetes Mellitus</org_study_id>
    <nct_id>NCT03313661</nct_id>
  </id_info>
  <brief_title>Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients</brief_title>
  <official_title>Co-administration of Cabergoline and Gliclazide Improve Glycemic Parameters and Lipid Profile in T2DM Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the glycemic efficacy of cabergoline on diabetic patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes mellitus (DM) is a progressive metabolic disorder that is associated with
      basal hyperinsulinemia, insulin resistance and impaired insulin release. Glycemic control is
      a fundamental part of the management of type 2 DM and difficult to achieve. Different
      antidiabetic agents can handle diabetic metabolic abnormalities. The development of
      antidiabetic agentswith novel mechanisms of action is highly desirable. Cabergoline, a long
      acting D2 agonist, is expected to play a role in the glycemic control.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 14, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The level of fasting and post prandial BG level</measure>
    <time_frame>4 months</time_frame>
    <description>Fasting and post prandial BG level will be measured after 4 months</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Cabergoline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gliclazide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>gliclazide (60-120 mg) once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabergoline</intervention_name>
    <description>cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide</description>
    <arm_group_label>Cabergoline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gliclazide</intervention_name>
    <description>gliclazide (60-120 mg)</description>
    <arm_group_label>Gliclazide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetic patients.

        Exclusion Criteria:

          -  Other drugs administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jouliana Atef Morcos, Msc</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Pharmacy, Tanta University, Egypt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abla Mohamed Ebeid, Ph D</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Pharmacy, AL-Delta University, Gamasa, Egypt</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samy Abdel kader khodeir, Ph D</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Medicine, Tanta University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gamal Abdel khalek Elazab, Ph D</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Pharmacy, Tanta University, Egypt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sherief Abd-Elsalam, consultant</last_name>
    <phone>00201095159522</phone>
    <email>Sheriefabdelsalam@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sherief Abd-Elsalam</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherief Abd-elsalam, lecturer</last_name>
      <phone>00201000040794</phone>
      <email>Sherif_tropical@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2017</study_first_submitted>
  <study_first_submitted_qc>October 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2017</study_first_posted>
  <last_update_submitted>October 14, 2017</last_update_submitted>
  <last_update_submitted_qc>October 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cabergoline</mesh_term>
    <mesh_term>Gliclazide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

